Loading...
Docoh

Selecta Biosciences (SELB)

Filed: 23 May 22, 8:00pm



 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549

 

SCHEDULE 13G

 

Under the Securities Exchange Act of 1934

(Amendment No.)*



Selecta Biosciences, Inc.

(Name of Issuer)

 

Common Stock, $0.0001 par value per share, including common shares obtainable upon exercise of Common Warrants

(Title of Class of Securities)

 

816212104

(CUSIP Number)

 

 

May 13, 2022
(Date of Event Which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

o Rule 13d-1(b)

x Rule 13d-1(c)

o Rule 13d-1(d)

 

 

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 


 

CUSIP No.  816212104
 SCHEDULE 13G
Page 2 of 9 Pages

 

     
1
NAME OF REPORTING PERSONS
 
Mangrove Partners Master Fund, Ltd.
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) x
(b) o
 
3
SEC USE ONLY
 
 
4
CITIZENSHIP OR PLACE OF ORGANIZATION
 
Cayman Islands
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
5
SOLE VOTING POWER
 
0
6
SHARED VOTING POWER
 
8,000,907(1)
7
SOLE DISPOSITIVE POWER
 
0
8
SHARED DISPOSITIVE POWER
 
8,000,907
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
8,000,907

10
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
 
 
o11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
 
5.14% (2)
12
TYPE OF REPORTING PERSON
 
OO

 
(1) Includes 3,752,258 common shares obtainable upon exercise of Common Warrants.
(2) This percentage is calculated based on the sum of (i) 151,809,416 Shares outstanding as of April 29, 2022, based on information provided by the Issuer and (ii) 3,752,258 Shares issuable upon exercise of the Common Warrants.
 


 

CUSIP No.  816212104
 SCHEDULE 13G
Page 3 of 9 Pages

 

     
1
NAME OF REPORTING PERSONS
 
Mangrove Partners
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) x
(b) o
 
3
SEC USE ONLY
 
 
4
CITIZENSHIP OR PLACE OF ORGANIZATION
 
Cayman Islands
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
5
SOLE VOTING POWER
 
0
6
SHARED VOTING POWER
 
8,000,907(1)
7
SOLE DISPOSITIVE POWER
 
0
8
SHARED DISPOSITIVE POWER
 
8,000,907
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
8,000,907

10
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
 
 
o11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
 
5.14% (2)
12
TYPE OF REPORTING PERSON
 
OO

 
(1) Includes 3,752,258 common shares obtainable upon exercise of Common Warrants
(2) This percentage is calculated based on the sum of (i) 151,809,416 Shares outstanding as of April 29, 2022, based on information provided by the Issuer and (ii) 3,752,258 Shares issuable upon exercise of the Common Warrants.
 


 

CUSIP No.  816212104
 SCHEDULE 13G
Page 4 of 9 Pages

 

     
1
NAME OF REPORTING PERSONS
 
Nathaniel August
2
CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) x
(b) o
 
3
SEC USE ONLY
 
 
4
CITIZENSHIP OR PLACE OF ORGANIZATION
 
United States
NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON
WITH
5
SOLE VOTING POWER
 
0
6
SHARED VOTING POWER
 
8,000,907(1)
7
SOLE DISPOSITIVE POWER
 
0
8
SHARED DISPOSITIVE POWER
 
8,000,907
9
AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
 
8,000,907

10
CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
 
 
o11
PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
 
5.14% (2)
12
TYPE OF REPORTING PERSON
 
IN, HC
 
(1) Includes 3,752,258 common shares obtainable upon exercise of Common Warrants
(2) This percentage is calculated based on the sum of (i) 151,809,416 Shares outstanding as of April 29, 2022, based on information provided by the Issuer and (ii) 3,752,258 Shares issuable upon exercise of the Common Warrants.
 


 

 

CUSIP No. 816212104
 SCHEDULE 13G
Page 5 of 9 Pages

 

Item 1.(a) Name of Issuer

Selecta Biosciences, Inc.

Item 1.(b) Address of Issuer’s Principal Executive Offices

65 Grove Street

Watertown, MA 02472

Item 2.(a, b, c) Names of Person Filing, Address of Principal Business Office, Citizenship:

Mangrove Partners, a Cayman Islands limited liability company, is located at c/o Maples Corporate Services, Ltd., PO Box 309, Ugland House, South Church Street, George Town, Grand Cayman, Cayman Islands KY1-1104

Mangrove Partners Master Fund, Ltd., a Cayman Islands limited liability company, is located at c/o Maples Corporate Services, Ltd., PO Box 309, Ugland House, South Church Street, George Town, Grand Cayman, Cayman Islands KY1-1104

Nathaniel August, a United States citizen, is located at 645 Madison Avenue, 14th Floor, New York, New York 10022

The shares of the Issuer which are the subject of this SCHEDULE 13G (the “Shares”) are held by the Master Fund. Beneficial ownership of the Shares is also claimed by (i) Mangrove Partners which serves as the investment manager of the Master Fund, and (ii) Nathaniel August who is the principal of Mangrove Partners.  

 

Item 2.(d) Title of Class of Securities

Common Stock, $0.0001 par value per share, including common shares obtainable upon exercise of Common Warrants

 

Item 2.(e) CUSIP No.:

816212104

 

CUSIP No.  816212104
 SCHEDULE 13G
Page 6 of 9 Pages

 

 

Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

 (a)¨Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
 
 (b)¨Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
 
 (c)¨Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
 
 (d)¨Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
 
 (e)oAn investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
 
 (f)¨An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
 
 (g)¨A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
 
 (h)¨A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
 
 (i)¨A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
 
 (j)¨A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
 
 (k)¨

A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                             

   Not Applicable

 

CUSIP No. 816212104
 SCHEDULE 13G
Page 7 of 9 Pages

 

 

Item 4. Ownership

Information with respect to the Reporting Persons' ownership of the Units as of May 5, 2022, is incorporated by reference to items (5) - (9) and (11) of the cover page of the respective Reporting Person.

The amount beneficially owned by each Reporting Person is determined based on the sum of (i) 151,809,416 Shares outstanding as of April 29, 2022, based on information provided by the Issuer and (ii) 3,752,258 Shares issuable upon exercise of the Common Warrants, as the Issuer reported in its Form 10-Q filed with the SEC on May 5, 2022.

The filing of this SCHEDULE 13G shall not be construed as an admission that the Reporting Persons are, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, the beneficial owners of any of the Shares reported herein. Each of the Reporting Persons specifically disclaims beneficial ownership of the Shares reported herein that are not directly owned by such Reporting Person.

Item 5. Ownership of Five Percent or Less of a Class

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ ].

Item 6. Ownership of More Than Five Percent on Behalf of Another Person

Not Applicable.

Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

Not Applicable.

Item 8. Identification and Classification of Members of the Group

See disclosures in Item 2 and Exhibit I.

Item 9. Notice of Dissolution of Group 

Not Applicable.

Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

 
CUSIP No. 816212104
 SCHEDULE 13G
Page 8 of 9 Pages

 

 

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: May 23, 2022

 

 

 

 

Mangrove Partners

     By: /s/ Nathaniel August  Nathaniel August, Director    
 

Mangrove Partners Master Fund, Ltd

    
 By: /s/ Nathaniel August
  Nathaniel August, Director
    
 

Nathaniel August

    
 By: /s/ Nathaniel August
  Nathaniel August
    

 

 
CUSIP No. 816212104
 SCHEDULE 13G
Page 9 of 9 Pages

 

Exhibit I

 

JOINT FILING STATEMENT

 

PURSUANT TO RULE 13d-1(k)

 

The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

 

Dated: May 23, 2022

 

 

Mangrove Partners

    
 By: /s/ Nathaniel August
  Nathaniel August, Director
    
 

Mangrove Partners Master Fund, Ltd

    
 By: /s/ Nathaniel August
  Nathaniel August, Director
    
 

Nathaniel August

    
 By: /s/ Nathaniel August
  Nathaniel August